Published in Pharmaceuticals (Basel) on July 13, 2010
Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med (1995) 6.56
Multiple control of interleukin-8 gene expression. J Leukoc Biol (2002) 5.35
Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med (1995) 4.82
p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nat Immunol (2001) 4.38
Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol (2002) 3.59
Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem (1997) 3.55
Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr (2007) 3.49
Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med (1995) 3.47
The role of chemokines in neutrophil biology. Front Biosci (2008) 3.10
Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med (2007) 2.63
CFTR inhibition mimics the cystic fibrosis inflammatory profile. Am J Physiol Lung Cell Mol Physiol (2006) 2.54
Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J (2001) 2.52
The CF salt controversy: in vivo observations and therapeutic approaches. Mol Cell (2001) 2.42
Activation of NF-kappaB in airway epithelial cells is dependent on CFTR trafficking and Cl- channel function. Am J Physiol Lung Cell Mol Physiol (2001) 2.36
Case-control study of acute renal failure in patients with cystic fibrosis in the UK. Thorax (2008) 2.32
Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med (1994) 2.26
Redox modulation of chromatin remodeling: impact on histone acetylation and deacetylation, NF-kappaB and pro-inflammatory gene expression. Biochem Pharmacol (2004) 2.23
Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am J Physiol Lung Cell Mol Physiol (2003) 2.20
Regulation of human airway epithelial cell IL-8 expression by MAP kinases. Am J Physiol Lung Cell Mol Physiol (2002) 2.19
Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med (1999) 2.08
Inflammation and infection in naive human cystic fibrosis airway grafts. Am J Respir Cell Mol Biol (2000) 1.94
Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr Pulmonol (2005) 1.90
High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr (2007) 1.86
Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med (2000) 1.78
A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr (1995) 1.75
Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med (2007) 1.75
Airway inflammation in cystic fibrosis. Chest (2008) 1.70
Molecular mechanisms of neutrophil recruitment elicited by bacteria in the lungs. Semin Immunol (2002) 1.70
Cytokines in innate host defense in the lung. J Clin Invest (2002) 1.66
Cystic fibrosis pathogens activate Ca2+-dependent mitogen-activated protein kinase signaling pathways in airway epithelial cells. J Biol Chem (2001) 1.49
Ibuprofen modulates NF-kB activity but not IL-8 production in cystic fibrosis respiratory epithelial cells. Respiration (2009) 1.46
Association between mucoid Pseudomonas infection and bronchiectasis in children with cystic fibrosis. Radiology (2009) 1.42
Cytokine secretion by cystic fibrosis airway epithelial cells. Am J Respir Crit Care Med (2003) 1.34
Tissue transglutaminase activation modulates inflammation in cystic fibrosis via PPARgamma down-regulation. J Immunol (2008) 1.32
Spectrum of CFTR mutations in cystic fibrosis and in congenital absence of the vas deferens in France. Hum Mutat (2000) 1.27
Proteases and cystic fibrosis. Int J Biochem Cell Biol (2008) 1.25
Dysregulated cytokine production in human cystic fibrosis bronchial epithelial cells. Inflammation (2001) 1.24
The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes. Chest (1999) 1.23
Activator protein-1 is the preferred transcription factor for cooperative interaction with nuclear factor-kappaB in respiratory syncytial virus-induced interleukin-8 gene expression in airway epithelium. J Infect Dis (1998) 1.20
Induced sputum inflammatory measures correlate with lung function in children with cystic fibrosis. J Pediatr (2002) 1.18
Decreased expression of peroxisome proliferator activated receptor gamma in cftr-/- mice. J Cell Physiol (2004) 1.17
Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? Fundam Clin Pharmacol (2006) 1.17
Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways. Proc Natl Acad Sci U S A (2008) 1.13
Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice. Respir Res (2006) 1.12
Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis. N Engl J Med (1998) 1.09
Signaling intermediates required for NF-kappa B activation and IL-8 expression in CF bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol (2002) 1.07
Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis. Am Rev Respir Dis (1990) 1.07
Reduced IL-10 secretion by CD4+ T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR). Clin Exp Immunol (1996) 1.06
Proinflammatory phenotype and increased caveolin-1 in alveolar macrophages with silenced CFTR mRNA. PLoS One (2010) 1.05
CHOP transcription factor mediates IL-8 signaling in cystic fibrosis bronchial epithelial cells. Am J Respir Cell Mol Biol (2007) 1.05
Neutrophil cell death, activation and bacterial infection in cystic fibrosis. Thorax (2005) 1.04
Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. J Pharmacol Exp Ther (2003) 1.04
Peroxisome proliferator-activated receptor-gamma in cystic fibrosis lung epithelium. Am J Physiol Lung Cell Mol Physiol (2008) 1.03
Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. J Pediatr (1991) 1.03
Oxidant-protease interaction in the lung. Prospects for antioxidant therapy. Chest (1996) 0.96
Ibuprofen: new explanation for an old phenomenon. Biochem Pharmacol (1999) 0.96
Oxidative stress induces extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase in cystic fibrosis lung epithelial cells: Potential mechanism for excessive IL-8 expression. Int J Biochem Cell Biol (2007) 0.95
Ibuprofen therapy for cystic fibrosis lung disease: revisited. Curr Opin Pulm Med (2008) 0.94
Role of IL-10 deficiency in excessive nuclear factor-kappaB activation and lung inflammation in cystic fibrosis transmembrane conductance regulator knockout mice. J Allergy Clin Immunol (2005) 0.93
The bronchoalveolar lavage fluid of cystic fibrosis lung transplant recipients demonstrates increased interleukin-8 and elastase and decreased IL-10. J Interferon Cytokine Res (1998) 0.92
What's new in CF airway inflammation: an update. Paediatr Respir Rev (2006) 0.91
Hyperinflammation in airways of cystic fibrosis patients: what's new? Expert Rev Mol Diagn (2008) 0.91
Oxidative changes of bronchoalveolar proteins in cystic fibrosis. Chest (2006) 0.89
Use of high-dose ibuprofen in a pediatric cystic fibrosis center. J Cyst Fibros (2006) 0.87
Modulation of transcription factor NF-kappaB by enantiomers of the nonsteroidal drug ibuprofen. Br J Pharmacol (1998) 0.87
High-dose ibuprofen therapy associated with esophageal ulceration after pneumonectomy in a patient with cystic fibrosis: a case report. BMC Pediatr (2004) 0.86
Glutathione and glutathione peroxidase in sputum samples of adult patients with cystic fibrosis. J Cyst Fibros (2004) 0.86
Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. Cochrane Database Syst Rev (2007) 0.84
Peroxisome proliferator-activated receptor alpha (PPAR alpha) down-regulation in cystic fibrosis lymphocytes. Respir Res (2006) 0.83
Cystic fibrosis HRCT scores correlate strongly with Pseudomonas infection. Pediatr Pulmonol (2009) 0.82
Induced sputum in cystic fibrosis: within-week reproducibility of inflammatory markers. Clin Biochem (2004) 0.80
Nonsteroidal anti-inflammatory drugs upregulate function of wild-type and mutant CFTR. Eur Respir J (2008) 0.80
Screening New Drugs for Immunotoxic Potential: II. Assessment of the Effects of Selective and Nonselective COX-2 Inhibitors on Complement Activation, Superoxide Anion Production and Leukocyte Chemotaxis and Migration Through Endothelial Cells. J Immunotoxicol (2005) 0.78
Diagnosing and managing infection in CF. Paediatr Respir Rev (2006) 0.77